Komori
Revision to earnings forecast4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Summary of Financial Results for the Nine Months Ended December 2023 (Japanese GAAP) (Non-consolidated)

The Company disclosed its previously unpublished full-year earnings forecast for the fiscal year ending March 2024 for the first time, projecting revenue of ¥7,800 million, an operating loss of ¥120 million, an ordinary loss of ¥80 million, and a net loss of ¥20 million. The dividend forecast remains undecided and has not been revised.

Worth reading
67In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2024 · Full year
Net Sales—→7,800million
—
Operating profit—→-120million
—
Ordinary income—→-80million
—
Profit attributable to owners of the parent—→-20million
—
Net income per share—→-0.58yen and sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

マキュエイド眼注用40㎎が出荷判定試験で不適合となり、2023年4月末から供給を停止していたため通期業績予想を未公表としていたが、売上高の見込みが立ったため今回開示した。

Details and amount of extraordinary loss

固定資産除却損5,428千円、棚卸資産廃棄損40,137千円、特別損失合計45,565千円

Dividend forecast revisionNo revision
Consolidated / non-consolidatedNon-consolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥7,800 million
Operating profitNot disclosed → ¥-120 million
Ordinary incomeNot disclosed → ¥-80 million
Profit attributable to owners of the parentNot disclosed → ¥-20 million
Net income per shareNot disclosed → -0.58 yen and sen
Fiscal Period CoveredFiscal year ending March 2024
Period CoveredFull year
Reason for the revisionマキュエイド眼注用40㎎が出荷判定試験で不適合となり、2023年4月末から供給を停止していたため通期業績予想を未公表としていたが、売上高の見込みが立ったため今回開示した。
Details and amount of extraordinary loss固定資産除却損5,428千円、棚卸資産廃棄損40,137千円、特別損失合計45,565千円
Dividend forecast revisionNo revision
Consolidated / non-consolidatedNon-consolidated
Items this document does not state (2)
Publication date of previous forecastPrevious-period results

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

「マキュエイド眼注用40㎎」が出荷判定試験で不適合となり、2023年4月末から供給を停止していたため通期業績予想を未公表としていましたが、売上高の見込みが立ったため、今回開示したとしています。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Nine Months Ended December 2023 (Japanese GAAP) (Non-consolidated) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori